Neuromodulation Vendors Confront MRI Challenges
As spinal cord stimulation and peripheral nerve stimulation technologies continue to advance, one feature that remains a consistent focus of clinical discussion—and a key differentiator among devices—is the ability (or lack thereof) for patients with active implantable systems to safely undergo MRI scans. Even as far back as the mid-1990s, when this editor was first involved in the cochlear implant…
Discure Technologies Targets Degenerative Disc Disease
Due to the unique anatomy of our skeletal system, certain components degrade faster than others. The intervertebral disc’s inner core (nucleus pulposus) is particularly vulnerable. Lacking blood vessels, this tissue depends entirely on fluid diffusion from the disc’s outer surface for oxygen, glucose, and waste removal. This diffusion process is facilitated , hydrophilic glycosaminoglycan molecules produced .
kHz Block Enables Selective Small-Fiber Activation in VNS
While the main focus of this newsletter is on clinical use of bioelectronic medicine, we occasionally cover animal research that has high clinical potential. Recently, Kip Ludwig’s team at the University of Wisconsin, with assistance from Warren Grill and Nicole Pelot at Duke University, published a preprint of their study, where five pigs were acutely stimulated with two VNS cuffs placed on the cervical vagus.
Neuromodulation Solutions Target “Transitional” Pain
Traditionally, implantable neuromodulation therapies have been reserved for patients with chronic, refractory pain, while noninvasive solutions like transcutaneous electrical nerve stimulation have long occupied the space of acute pain management. However, new devices increasingly supported targeting the critical window between acute and chronic pain—whether for post-operative pain or lower back pa…
Failure Modes
The field of neuromodulation has seen a number of therapeutic and commercial success stories in the 25 years that we have been publishing this newsletter. When a new therapy or commercial device experiences a successful outcome, there is no shortage of coverage in the general press, in scientific journals, and at clinical society meetings. But when a device or therapy experiences failure, there is often very little coverage of what went wrong.
Neurotech Entrepreneurs Make Presentations at LSI USA 25
Neurotech Business Report Executives from several neurotechnology firms joined hundreds of other medtech professionals at the LSI USA 25 conference, held in Dana Point, CA earlier this month. The conference featured several keynotes and panel discussions related to investment, partnering, reimbursement, and other key topics. Lisa Earnhardt, group president of medical devices at Abbott, gave a keynote on the second day of the meeting.
Pain Neuromodulation Market to Reach $6.5 Billion by 2030
Neurotech Reports, the publisher of the newsletter Neurotech Business Report , announced the availability of a new market research report that forecasts the growth of the worldwide market for implanted pain neuromodulation systems. According to the newly published report, The Market for Implanted Pain Neuromodulation Systems: 2025-2030, the worldwide market will be $3.37 billion in 2025, growing to $6.49 billion by 2030, which represents a 12% compound annual growth rate.
Industry Professionals Attend 2024 Neurotech Leaders Forum
About 120 neurotech industry professionals attended the 24th annual Neurotech Leaders Forum in San Francisco earlier this month. Keynote speaker Ray Cohen, CEO of Axonics Inc., gave a timely and evocative keynote address on the first day of the conference, just days before Boston Scientific’s $3.7 billion deal for Axonics closed. Cohen provided a number of details from his tenure at Axonics culminating with the Boston Scientific deal, but he also offered words of advice to neurotech startups.
Neuroprosthetics Applications Continue to Evolve
The field of neuroprosthetics has seen a number of advancements in recent months, as investigators at research institutions in the U.S. and Europe have reported progress, and as device firms active in the space have announced product enhancements and other commercialization milestones. On the research front, European and American investigators reported breakthroughs in two areas impacting individuals with spinal cord injury: restoring locomotion and restoring sensation.
Promising Firms to Present at 2025 Bioelectronic Medicine Forum in NYC
Promising Firms to Present at 2025 Bioelectronic Medicine Forum in NYC Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that several new startup and emerging bioelectronic medicine firms will present at the the Eighth Annual Bioelectronic Medicine Forum. The event will take place on April 10, 2025 at the New York Academy of Medicine in Manhattan.